Agenus(US:AGEN)2023-02-10 16:10Agenus Highlights - Agenus's Botensilimab is an Fc-enhanced anti-CTLA-4 antibody with broad franchise potential, showing unprecedented clinical responses in 9 cold and treatment-resistant cancers[6] - Agenus has a deep clinical pipeline addressing complementary mechanisms, with 12 clinical-stage antibody programs advancing in 12 unique combinations, by Agenus and through partnerships[6] - Agenus has a proven R&D engine with a track record of value creation through strategic partnerships, generating >$825 million in cash through partnerships, with potential $27 billion milestones remaining[6] Business Development and Financial Status - Agenus has received $825 million in cash from partnerships and transactions[12] - Agenus has $27 billion in potential future milestone payments, in addition to royalties[12] - Agenus had $218 million cash in hand as of September 30, 2022[24] Botensilimab Clinical Data - Botensilimab shows a 23% ORR in MSS CRC with 70 evaluable patients, versus 1-5% ORR for SOC[28] - Botensilimab shows a 26% ORR in Ovarian cancer with 19 evaluable patients, versus 3-10% ORR for SOC[28] - Botensilimab shows a 46% ORR in Sarcoma with 13 evaluable patients, versus 12-16% ORR for SOC[28] - Botensilimab shows a 60% ORR in PD-(L)1 Refractory NSCLC with 5 evaluable patients, versus 6-13% ORR for SOC[28] Partnered Programs - BMS-986442 (AGEN1777) has potential milestone payments of $134 billion and up to mid-teens royalties[12] - INCAGN1876, INCAGN2390, INCAGN2385 have potential milestone payments of $570 million and up to mid-teens royalties[12] - Zalifrelimab (local delivery in urinary tract) has potential milestone payments of $450 million and up to low double-digit royalties[12] - Balstilimab & zalifrelimab (Greater China) have potential milestone payments of $200 million and up to low-twenties royalties[12] - MK-4830 has potential milestone payments of $100 million[12]